We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Can we Use Intravenous Injection of Tranexamic Acid in Routine Practice With Active Management of the Third Stage of Labor?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01338454
Recruitment Status : Completed
First Posted : April 19, 2011
Last Update Posted : November 17, 2011
Information provided by (Responsible Party):
Kemal GUNGORDUK, Erzincan Military Hospital

Brief Summary:

Obstetrical hemorrhage accounts for nearly one quarter of all maternal deaths worldwide and was the most common cause of maternal death in the Turkey [1,2]. Most of these deaths occur within 4 h of delivery and are a result of problems during third and fourth stages of labor. It also contributes significantly to serious maternal morbidity. Obstetric, surgical and radiological interventions play central role in the management of obstetric hemorrhage; however, pharmacologic management and in particular prohemostatic therapies also play an important role in the final maternal outcome. Administration of tranexamic acid (TA), intravenously in the third stage of labor may be one of these methods.

TA a synthetic derivate of the amino acid lysine, is an antifibrinolytic that reversibly inhibits the activation of plasminogen, thus inhibiting fibrinolysis and reducing bleeding. TA may enhance the effectiveness of the patient's own hemostatic mechanism [3,4]. In nonobstetric surgery, a systematic review of randomized controlled trails showed that tranexamic acid reduced the risk of blood transfusion [ relative risk (RR) 0.61; 95% CI 0.54-0.69] and also reduced the need for re-operation as a result of bleeding (RR 0.67; 95% CI 0.41-1.09). There was no evidence for an increased risk of thrombotic events [5].

In gynecology and obstetrics, TA is most commonly used to treat idiopathic menorrhagia, and is an effective and well-tolerated treatment when administered orally [5,6,7]. Bleeding associated with pregnancy (placental abruption, placenta previa) has also been treated with TA [6]. Furthermore, four randomized controlled studies have shown that TA reduces postpartum hemorrhage (PPH) following cesarean delivery [7-11]. Only one randomized trail is available evaluating the effect of TA use to prevent bleeding in the postpartum period following spontaneous vaginal delivery [12].

The purpose of our study was to estimate the effect of the addition of intravenous TA to a standard active management of the third stage of labor (which includes prophylactic injection of 10 IU of oxytocin within two minutes of birth, early clamping of the umbilical cord, and controlled cord traction).

Condition or disease Intervention/treatment Phase
Obstetrical Hemorrhage Drug: transamin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Study Start Date : March 2011
Primary Completion Date : August 2011
Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: tranexamic acid
TA administered intravenously over a 5 min period at delivery of the anterior shoulder
Drug: transamin
TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
No Intervention: saline
10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder

Primary Outcome Measures :
  1. The amount of blood loss in the third and fourth stages (the fourth stage of labor begins with delivery of the placenta and ends 2 hours after delivery) of labor. [ Time Frame: 2 hours ]
    The volume of blood loss was measured by weighing a sheet soaked from the end of the delivery to 2h after birth. We used a specially designed operating sheet and an electronic scale to weigh all the material (with a 1 g deviation range). The quantity of blood (ml) = (weight of used materials - weight of materials prior to use)/1.05.

Secondary Outcome Measures :
  1. incidences of PPH >500 ml [ Time Frame: 2 hours ]
    The quantity of blood (ml) = (weight of used materials - weight of materials prior to use)/1.05 > 500 mL

  2. the incidences of severe postpartum hemorrhage [ Time Frame: 2 hours ]
    The quantity of blood (ml) = (weight of used materials - weight of materials prior to use)/1.05 ≥1000 ml

  3. need for additional uterotonic drugs [ Time Frame: 2 hours ]
    need for additional uterotonic drugs such as 200 µg intravenous metylergometrine, 20 IU oxytocin infusion in 500 ml ringer lactate, and/or 800 misoprostol rectally for vaginal bleeding

  4. side effects at time of TA injection [ Time Frame: 2 hours ]
    nausea, vomiting or diarrhea

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • gestational age between 37 and 42 weeks,
  • live fetus,
  • cephalic presentation,
  • vaginal birth.
  • Patients who had a risk factors for PPH, such as multiple gestation, polyhydramnios, fetal macrosomia, antepartum hemorrhage, anemia (haemoglobin concentration < 8 g/dL), severe pre-eclampsia, or coagulopathy

Exclusion Criteria:

  • placenta previa,
  • placental abruption,
  • cesarean section or any uterine scar, abnormal placentation (accreta, increta, or percreta),
  • a current or previous history of significant disease, including heart disease, liver, renal disorders.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01338454

Bakıryok Women and Children Hospital
İstanbul, Bakırkoy, Turkey, 34142
Sponsors and Collaborators
Erzincan Military Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kemal GUNGORDUK, medical doctor, Erzincan Military Hospital
ClinicalTrials.gov Identifier: NCT01338454     History of Changes
Other Study ID Numbers: gungorduk12
First Posted: April 19, 2011    Key Record Dates
Last Update Posted: November 17, 2011
Last Verified: November 2011

Additional relevant MeSH terms:
Pathologic Processes
Tranexamic Acid
Antifibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action